FASUDIL HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H17N3O2S.ClH
Molecular Weight	327.83
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.O=S(=O)(N1CCCNCC1)C2=CC=CC3=C2C=CN=C3

InChI

InChIKey=LFVPBERIVUNMGV-UHFFFAOYSA-N

InChI=1S/C14H17N3O2S.ClH/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14;/h1,3-5,7,11,15H,2,6,8-10H2;1H

HIDE SMILES / InChI

Molecular Formula	C14H17N3O2S
Molecular Weight	291.369
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://library.corporate-ir.net/library/17/177/177285/items/203435/FasudilfactsheetJune262006.pdf

Fasudil is a potent Rho kinase inhibitor, which was developed by Asahi Kasei. The drug is used in Asia for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Rho-associated protein kinase 7 Target ID: CHEMBL2111459 Sources: http://library.corporate-ir.net/library/17/177/177285/items/203435/FasudilfactsheetJune262006.pdf	Inhibitor 8297		0.4 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cerebral vasospasm 9 Sources: http://www.pharm.or.jp/eng/126th/data/AL07.pdf	Preventing		Approved 8429	ERIL Approved Use Improvement of cerebral vasospasm and cerebral ischemic symptoms associated with cerebral vasospasm after subarachnoid hemorrhage.

PubMed

Title	Date	PubMed
Microtubule disruption modulates the Rho-kinase pathway in vascular smooth muscle.	2001	11519742
Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage.	2001 Apr	11322450
Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes.	2001 Aug	11483085
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.	2001 Aug 10	11531167
Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.	2001 Dec 1	11751708
Calyculin-A induces focal adhesion assembly and tyrosine phosphorylation of p125(Fak), p130(Cas), and paxillin in Swiss 3T3 cells.	2001 Jul	11382927
Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia.	2001 Mar	11372552
Myotonic dystrophy protein kinase phosphorylates the myosin phosphatase targeting subunit and inhibits myosin phosphatase activity.	2001 Mar 30	11287000
Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels.	2001 Sep	11522599
Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats.	2001 Sep 7	11553365
[Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].	2002 Aug	12382411
Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.	2002 Jun 12	12063175
Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction.	2002 Nov 29	12445583
Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension.	2003	14713118
Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil.	2003 Apr	12943196
Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm.	2003 Apr 18	12637369
Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1.	2003 Aug 22	12783890
Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine.	2003 Jan	12522098
A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.	2003 Jan 3	12480155
Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.	2003 Jul 11	12871759
Astrocyte stellation induced by Rho kinase inhibitors in culture.	2003 Jun 12	12763584
Protein kinase C is necessary for recovery from the thyrotropin-releasing hormone-induced r-ERG current reduction in GH3 rat anterior pituitary cells.	2003 Mar 15	12562894
Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone.	2003 May-Jun	12902637
Effects of HA-1077 and Y-27632, two rho-kinase inhibitors, in the human umbilical artery.	2004	15509884
[Rho-kinase inhibitor].	2004 Feb	15035192
Differential effects of Rho-kinase inhibition on artery wall mass and remodeling.	2004 Jan	14718843
Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms.	2004 Jan	14592842
The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis.	2004 Jan-Feb	14993932
Rho kinase inhibition initiates apoptosis in human airway epithelial cells.	2004 Mar	12933355
Inhibition of protein kinase C-mediated contraction by Rho kinase inhibitor fasudil in rabbit aorta.	2004 Nov	15459803
Mechanisms underlying postjunctional synergism between responses of the vas deferens to noradrenaline and ATP.	2004 Sep 13	15364001
Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin.	2005 Jan-Feb	15627783
Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage.	2005 Jun	15665056

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 30 mg fasudil hydrochloride should be diluted in 50-100 mL solution and administered by intravenous infusion over 30 minutes 2-3 times daily.

Route of Administration: Intravenous

In Vitro Use Guide

The rat aortic rings were contracted by KCl; when the contraction reached a plateau, fasudil was added at concentrations from 10(-9) to 10(-5) M. The relaxation IC50 was 0.74 uM. When rabbit aortic rings were used, IC50 values were 37,15 uM and 27,54 uM for KCl and Methoxamine-induced contraction, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:43:08 GMT 2023` Edited by `admin` on `Fri Dec 15 19:43:08 GMT 2023`
Record UNII	SQ04N8S7BR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FASUDIL HYDROCHLORIDE

Common Name

English

FASUDIL HYDROCHLORIDE [MART.]

Common Name

English

1H-1,4-DIAZEPINE, HEXAHYDRO-1-(5-ISOQUINOLINYLSULFONYL)-, MONOHYDROCHLORIDE

Common Name

English

Fasudil hydrochloride [WHO-DD]

Common Name

English

ISOQUINOLINE, 5-((HEXAHYDRO-1H-1,4-DIAZEPIN-1-YL)SULFONYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

FASUDIL HYDROCHLORIDE [JAN]

Common Name

English

FASUDIL HYDROCHLORIDE [MI]

Common Name

English

5-(HEXAHYDRO-1H-1,4-DIAZEPINE-1-YLSULFONYL)ISOQUINOLINE HYDROCHLORIDE

Systematic Name

English

ERIL

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

815421